News | Mobile Devices | June 13, 2018

Medisafe Demonstrates Double-Digit Impact on Hypertension Medication Adherence

Use of medication management mobile app increased prescription refill rates by almost 10 percent

Medisafe Demonstrates Double-Digit Impact on Hypertension Medication Adherence

June 13, 2018 — Medication management platform Medisafe released data showing that, on average, hypertensive patients increase their prescription refills by almost 10 percent after they start using the company's mobile app.

In order to determine the increase in prescription claims, the study matched Medisafe users to their refill data using a HIPAA-compliant, non-identification process. The investigators calculated a medication possession ratio ("MPR") for each of the over 4,000 patients taking an antihypertensive medication pre-app (before the patient started using Medisafe) and on-app (once the patient started using Medisafe) and grouped them into corresponding MPR deciles (0 - 0.1 being the least adherent, 0.9 - 1.0 being the most adherent). MPR is a standard metric used by the healthcare industry to track medication adherence, in which an MPR of 1.0 corresponds to a 100 percent refill rate.  

Key findings include:

  • Of patients not in the top MPR decile pre-app, 82 percent (1,371 of 1,667) increased by at least one decile on-app;
  • Of patients with a pre-app MPR < 0.8, 78 percent (920 of 1,179) increased by at least 2 deciles;
  • Of patients with a pre-app MPR < 0.5, 74 percent of patients (320 of 431) increased by at least 5 deciles; and
  • The proportion of patients with MPR ≥ 0.80 increased from 70.8 percent pre-app to 86.25 percent on-app, a 21.8 percent relative increase.

 

Summary Table

Adherence (MPR) Pre-app On-app p-value % change
Mean 0.84 0.92 <.0001 9.52%
Standard deviation 0.23 0.13    
Adherent [MPR ≥ 0.80] 2858 (71%) 3482 (86%) <.0001 21.13%

N= 4,037

 

The hypertension results follow data released from the same landmark study in early March on the accuracy of Medisafe's patient reported adherence data. In the coming months, Medisafe will continue to release results, including data regarding the platform's impact on adherence and persistence across other therapeutic areas.

For more information: www.medisafe.com


Related Content

News | Cardiovascular Clinical Studies

May 6, 2026 — Image Analysis Group (IAG), a global imaging CRO headquartered in London, U.K., and HeartcoR Solutions ...

Home May 06, 2026
Home
News | Cardiovascular Clinical Studies

April 9, 2026 — Mount Sinai researchers have created an analytic tool using machine learning that can predict ...

Home April 14, 2026
Home
News | Cardiovascular Clinical Studies

April 13, 2026 —The American Heart Association (AHA) has granted Case Western Reserve University the Rapid Impact ...

Home April 13, 2026
Home
News | Cardiovascular Clinical Studies

April 2, 2026 — Iterative Health and US Heart & Vascular (USHV) have announced a strategic partnership to advance ...

Home April 02, 2026
Home
News | Cardiovascular Clinical Studies

March 4, 2026 — UltraSight, a provider of AI-guided cardiac imaging workflows, has announced Late-Breaking clinical ...

Home March 04, 2026
Home
News | Cardiovascular Clinical Studies

Feb. 9, 2026 — HTA and MedAxiom have opened applications for the 2026 HeartX program, a cardiovascular-focused ...

Home February 18, 2026
Home
News | Cardiovascular Clinical Studies

Jan. 5, 2026 — Medera Inc., a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by ...

Home January 05, 2026
Home
News | Cardiovascular Clinical Studies

Nov. 10, 2025 —Genomics, a science-led techbio company, has today announced new research that suggests polygenic risk ...

Home November 12, 2025
Home
News | Cardiovascular Clinical Studies

Oct. 21, 2025 – AskBio Inc., a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG ...

Home October 21, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 25, 2025 — Merck, known as MSD outside of the United States and Canada, has announced that new clinical trial and ...

Home August 25, 2025
Home
Subscribe Now